anaphylaxis, acute allergic reactions, and angioedema
DESCRIPTION
TRANSCRIPT
![Page 1: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/1.jpg)
Anaphylaxis, Acute Allergic Reactions, and
Angioedema
![Page 2: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/2.jpg)
ANAPHYLAXIS AND ALLERGIC REACTIONS
![Page 3: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/3.jpg)
![Page 4: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/4.jpg)
![Page 5: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/5.jpg)
Clinical Features
Majority: signs and symptoms begin suddenly, often within 60 minutes of exposure
biphasic phenomenon 3-20% of patients caused by a second phase of mediator release,
peaking 4-8 hours after the initial exposure and exhibiting itself clinically 3-4 hours after the initial clinical manifestations have cleared
late-phase allergic reaction primarily mediated by the release of newly generated
cysteinyl leukotrienes, the former slow-reacting substance of anaphylaxis
![Page 6: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/6.jpg)
Diagnosis
Serum tryptase levels
![Page 7: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/7.jpg)
![Page 8: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/8.jpg)
Treatment
![Page 9: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/9.jpg)
Treatment
![Page 10: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/10.jpg)
Treatment
![Page 11: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/11.jpg)
Disposition and Follow-Up
Admission/DischargeAdmission to hospital is rareAll unstable patients with anaphylaxis refractory
to treatment or where airway interventions were required should be admitted to the intensive care unit.
Patients who receive epinephrine should be observed in the ED, but the duration of observation is based on experience rather than clear evidence.
![Page 12: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/12.jpg)
Disposition and Follow-Up
Admission/DischargeIf patients remain symptom free after
appropriate treatment following 4 hours of observation, the patient can be safely discharged home.
prolonged observation periods should be considered in patients with a past history of severe reaction and those using -blockers
![Page 13: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/13.jpg)
Disposition and Follow-Up
![Page 14: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/14.jpg)
URTICARIA AND ANGIOEDEMA
![Page 15: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/15.jpg)
Urticaria
Treatment of urticarial reactions is generally supportive and symptomatic, with attempts to identify and remove the offending agent.
Antihistamines, with or without corticosteroids, are usually sufficient, although epinephrine can be considered in severe or refractory cases.
The addition of a histamine-2 receptor blocker, such as ranitidine, may also be useful in more severe, chronic, or unresponsive cases.
![Page 16: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/16.jpg)
Angioedema
Angioedema of the tongue, lips, and face has the potential for airway obstruction.
Management is supportive, with special attention to the airway, which can become occluded rapidly and unpredictably.
Epinephrine, antihistamines, and steroids are often still used, but benefits have not been clearly demonstrated.
![Page 17: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/17.jpg)
Angioedema
Patients with mild swelling and no evidence of airway obstruction can be observed in the ED and discharged if swelling diminishes.
Patients with moderate to severe swelling, dysphagia, or respiratory distress are best admitted for close observation.
![Page 18: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/18.jpg)
Take home message
![Page 19: Anaphylaxis, acute allergic reactions, and angioedema](https://reader033.vdocuments.mx/reader033/viewer/2022061111/5455cf37af7959d8748b9ca7/html5/thumbnails/19.jpg)
ANY QUESTION?